Irska - angleščina - HPRA (Health Products Regulatory Authority)

milpharm limited - cefuroxime axetil (amorphous) - film coated tablet - 250 milligram - cephalosporins and related substances - antibacterials for systemic use, second-generation cephalosporins - cefuroxime milpharm is indicated for the treatment of the infections listed below in adults and children from the age of 3 months • acute streptococcal tonsillitis and pharyngitis. • acute bacterial sinusitis. • acute otitis media. • acute exacerbations of chronic bronchitis. • cystitis. • pyelonephritis. • uncomplicated skin and soft tissue infections. • treatment of early lyme disease.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

a-s medication solutions - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. -  the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute ba

Izrael - angleščina - Ministry of Health

novartis israel ltd., israel - cefuroxime as axetil - granules for suspension - cefuroxime as axetil 25 mg/ml - cefuroxime - cefuroxime - zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months.• acute streptococcal tonsillitis and pharyngitis.• acute bacterial sinusitis.• acute otitis media.• acute exacerbations of chronic bronchitis.• cystitis.• pyelonephritis.• uncomplicated skin and soft tissue infections. • treatment of early lyme disease.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Izrael - angleščina - Ministry of Health

novartis israel ltd., israel - cefuroxime as axetil - granules for suspension - cefuroxime as axetil 50 mg/ml ml - cefuroxime - cefuroxime - zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months.• acute streptococcal tonsillitis and pharyngitis.• acute bacterial sinusitis.• acute otitis media.• acute exacerbations of chronic bronchitis.• cystitis.• pyelonephritis.• uncomplicated skin and soft tissue infections. • treatment of early lyme disease.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 1577.7 mg (equivalent: cefuroxime, qty 1500 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 788.9 mg (equivalent: cefuroxime, qty 750 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

h.j. harkins company, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg -   - pharyngitis/tonsillitis caused by streptococcus pyogenes.   note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. there are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of streptococcus pyogenes.   - acute bacterial otitis media caused by streptococcus pneumoniae , haemophilus influenzae (including beta-lactamase–producing strains), moraxella catarrhalis (including beta-lactamase–producing strains), or streptococcu

Združene države Amerike - angleščina - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacte

Združene države Amerike - angleščina - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets, usp in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets, usp in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus   pneumoniae , haemophilus influenzae (including β - lactamase-producing strains), moraxella catarrhalis (including β - lac

Združene države Amerike - angleščina - NLM (National Library of Medicine)

american health packaging - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes. cefuroxime axetil tablets are indicated for the treatment of adult a